As a physician and veteran, I am driven by a duty to serve and a commitment to doing what is right. In the military, we understood that every resource must be optimized for the mission. In medicine, we are taught that our primary duty is to the patient. Unfortunately, the federal 340B Drug Pricing Program, originally designed to help safety-net providers stretch scarce resources to serve the vulnerable, has strayed far from this noble objective.
What was once a targeted and compassionate initiative has morphed into a massive, unchecked profit engine for non-profit hospitals. Congress created the 340B program in 1992 to require pharmaceutical manufacturers to provide steep drug discounts to hospitals serving low-income communities. The goal was simple: use the savings to subsidize care for the uninsured and under-insured. Today, however, many nonprofit hospitals use the program to engage in a lucrative form of arbitrage—purchasing medications at deep discounts and billing insurers at full price, pocketing the massive spread.
This is both a policy failure and a massive betrayal of taxpayer’s trust. Research consistently shows that participation in the 340B program does not guarantee better outcomes for the needy. A 2026 national analysis of nearly 4,000 hospitals found that 340B-participating institutions actually provide, on average, lower levels of charity care—measured as a percentage of operating expenses—than their non-participating counterparts.
These hospitals essentially receive the absolute lowest acquisition price for drugs while charging patients and commercial insurers the highest possible rates – oftentimes keeping the discounts themselves to pad their bank accounts, rather than help patients afford care. They are leveraging their status to prioritize bottom-line growth over patient access. Instead of lowering out-of-pocket costs for families, these untracked funds are too often diverted to finance administrative bloat, lavish executive compensation, and the expansion of high-margin drug discounts even in affluent areas.
The bottom line? We need transparency and accountability. The Tax Exempt Hospital Transparency Act (H.R. 9504) is a vital step toward holding these institutions accountable by requiring them to disclose exactly how much they earn through 340B and how they use those funds. We must demand clear receipts to ensure that if a hospital receives a taxpayer-funded discount, the patient—not the hospital’s balance sheet—is the primary beneficiary.
True healthcare reform requires us to return to the program’s original scope. Congress must stop treating 340B as a corporate slush fund and start treating it as a sacred trust. It’s time to mandate that these discounts are tied directly to patient care, ensuring that our safety-net system actually serves the people it was built to protect.
– – –
Dr. Omar Hamada, MD, MBA, MATS, is a physician, healthcare entrepreneur, and retired U.S. Army Lieutenant Colonel. A veteran of 14 years of military service, he served with U.S. Army Special Forces and was awarded the Bronze Star. Dr. Hamada is board-certified in both Family Medicine and Obstetrics & Gynecology, with extensive experience in emergency medicine.
